<DOC>
	<DOCNO>NCT00608023</DOCNO>
	<brief_summary>HIV lipodystrophy affect significant proportion patient treat combination antiretroviral therapy ( ART ) characterize excess visceral fat accumulation , loss extremity subcutaneous fat , association dyslipidemia insulin resistance . Data first Phase 3 multicenter , randomize , placebo-controlled trial demonstrate daily administration 2mg TH9507 , growth hormone release factor ( GRF ) , HIV- infect patient excess abdominal fat accumulation 26 week result decrease visceral adipose tissue ( VAT ) trunk fat , less change limb fat subcutaneous adipose tissue ( SAT ) . The present study aim confirm observation make first Phase 3 study .</brief_summary>
	<brief_title>TH9507 Extension Study Patients With HIV- Associated Lipodystrophy</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>HIV-Associated Lipodystrophy Syndrome</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Growth Hormone-Releasing Hormone</mesh_term>
	<criteria>Subjects complete 26 week treatment period TH9507CTR1011 study . Signed informed consent trialrelated activity . Fasting blood glucose &gt; 8.33 mmoL ( 150 mg/dL ) end TH9507CTR1011 study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>HIV</keyword>
	<keyword>Lipodystrophy</keyword>
	<keyword>Abdominal fat accumulation</keyword>
	<keyword>Growth hormone release hormone</keyword>
	<keyword>HIV-associated lipodystrophy</keyword>
	<keyword>Treatment experience</keyword>
</DOC>